Literature DB >> 27065657

Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Narendra Hulikal1, Sivanath Reddy Gajjala1, Teck Chand Kalawat2, Radhika Kottu3, Lakshmi Amancharla Yadagiri4.   

Abstract

In India up to 50 % of breast cancer patients still present as locally advanced breast cancer (LABC). The conventional methods of metastatic work up include physical examination, bone scan, chest & abdominal imaging, and biochemical tests. It is likely that the conventional staging underestimates the extent of initial spread and there is a need for more sophisticated staging procedure. The PET/CT can detect extra-axillary and occult distant metastases and also aid in predicting response to chemotherapy at an early point in time. To evaluate the utility of FDG PET/CT in initial staging and response assessment of patients with LABC receiving NACT. A prospective study of all biopsy confirmed female patients diagnosed with LABC receiving NACT from April 2013 to May 2014. The conventional work up included serum chemistry, CECT chest and abdomen and bone scan. A baseline whole body PET/CT was done in all patients. A repeat staging evaluation and a whole body PET/CT was done after 2/3rd cycle of NACT in non-responders and after 3/4 cycles in clinical responders. The histopathology report of the operative specimen was used to document the pathological response. The FDG PET/CT reported distant metastases in 11 of 38 patients, where as conventional imaging revealed metastases in only 6. Almost all the distant lesions detected by conventional imaging were detected with PET/CT, which showed additional sites of metastasis in 3 patients. In 2 patients, PET/CT detected osteolytic bone metastasis which were not detected by bone scan. In 5 patients PET CT detected N3 disease which were missed on conventional imaging. A total of 14 patients had second PET/CT done to assess the response to NACT and 11 patients underwent surgery. Two patients had complete pathological response. Of these 1 patient had complete metabolic and morphologic response and other had complete metabolic and partial morphologic response on second PET/CT scan. The 18 FDG PET/CT can detect more number of metastasis as well as additional sites of metastasis compared to conventional methods. The response assessment resulted in change of treatment regimen in 14 % of patients.

Entities:  

Keywords:  18F FDG PET/CT for staging; Locally advanced breast cancer; Neoadjuvant chemotherapy response assessment

Year:  2015        PMID: 27065657      PMCID: PMC4809846          DOI: 10.1007/s13193-015-0421-0

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  24 in total

1.  [Primary chemotherapy in the treatment of breast cancer].

Authors:  G Auclerc; C Borel; D Khayat; C Soubrane; M Weil
Journal:  Ann Chir Plast Esthet       Date:  1992-12       Impact factor: 0.660

2.  Monitoring primary breast cancer throughout chemotherapy using FDG-PET.

Authors:  Garry M McDermott; Andrew Welch; Roger T Staff; Fiona J Gilbert; Lutz Schweiger; Scott I K Semple; Tim A D Smith; Andrew W Hutcheon; Iain D Miller; Ian C Smith; Steven D Heys
Journal:  Breast Cancer Res Treat       Date:  2006-08-09       Impact factor: 4.872

3.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

Authors:  G Bonadonna; P Valagussa; C Brambilla; L Ferrari; A Moliterni; M Terenziani; M Zambetti
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

4.  Breast Cancer Care in India: The Current Scenario and the Challenges for the Future.

Authors:  Gaurav Agarwal; Pooja Ramakant
Journal:  Breast Care (Basel)       Date:  2008-02-22       Impact factor: 2.860

5.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

6.  Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

Authors:  Edwin R Fisher; Jiping Wang; John Bryant; Bernard Fisher; Eletherios Mamounas; Norman Wolmark
Journal:  Cancer       Date:  2002-08-15       Impact factor: 6.860

7.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Authors:  S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

8.  Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study.

Authors:  R H de Boer; A Saini; S R Johnston; M E O'Brien; P A Ellis; M W Verrill; J A Prendiville; G Walsh; S Ashley; I E Smith
Journal:  Breast       Date:  2000-06       Impact factor: 4.380

9.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

10.  Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

Authors:  Gunter von Minckwitz; Hans-Peter Sinn; Günter Raab; Sibylle Loibl; Jens-Uwe Blohmer; Holger Eidtmann; Jörn Hilfrich; Elisabeth Merkle; Christian Jackisch; Serban D Costa; Angelika Caputo; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2008-04-01       Impact factor: 6.466

View more
  2 in total

1.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

2.  Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer.

Authors:  A Arnaout; N P Varela; M Allarakhia; L Grimard; A Hey; J Lau; L Thain; A Eisen
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.